GLP1R and type 2 diabetes mellitus: At present, the ADA “Standards of Medical Care in Diabetes 2021” continues to recommend that patients with both type II diabetes and ASCVD be prescribed either an SGLT-2 inhibitor or a GLP-1 agonist for cardioprotective benefit, in addition to metformin, regardless of A1c [7].